CMPX at a glance
Compass Therapeutics, Inc. (CMPX, SEC CIK 1738021) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Compass Therapeutics, Inc. (CMPX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $66.5 million. Diluted EPS was -$0.42.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Compass Therapeutics, Inc. (CMPX) shares worth $49.4 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Lerner Neil on November 17, 2026 of 10,000 shares at $0.59 per share.
- In the last 90 days, CMPX insiders reported 3 open-market purchases ($27K) and 0 open-market sales ($0) on Form 4, a net purchase of $27K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$27K
- 13F holders
- 25 funds
- $49.4M · −1 vs prior quarter
- Latest 8-K
- Nov 20, 2026
- Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Operating margin -107.0% vs -110.9% YoY, based on operating losses of $28.8 million and $15.8 million
- Tovecimig highest R&D spending, $14.4 million vs $3.3 million YoY
- Cash, equivalents and marketable securities $163 million, funding operations into 2028
- Operating cash use $48.3 million, up from $35.9 million YoY; FDA recommended survival-benefit trial before tovecimig BLA
Risk Factors
- New corporate-governance risk: bylaws adopted exclusive Delaware and Massachusetts forums for specified stockholder litigation
- Regulatory and legal risk: Securities Act claims restricted to U.S. District Courts in Delaware or Massachusetts
- Macroeconomic risk: July 2026 U.S. tariffs of approximately 10% to 12.5% increased potential research and development costs
- Operational risk: macroeconomic disruptions could delay clinical-trial initiation or expansion and material supply availability
- Financial risk: deteriorating equity and credit markets could make future financing costlier, more dilutive, or unavailable
AI summary of the CMPX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days
- Immediate delisting not triggered: shares continue trading on Nasdaq Capital Market
Item 2.02: Results of Operations and Financial Condition
- Press release covers Compass Therapeutics’ quarter and nine months ended September 30, 2026
- Financial results and management commentary are contained in Exhibit 99.1, relevant for assessing operating performance and cash position
Item EX-99.1: Item EX-99.1
- Q3 net loss $27.2M, or $0.15 per share, versus $14.3M, or $0.08, as pipeline investment accelerated
- Cash and marketable securities $163M, down from $209M at December 31, 2025, funding operations into 2028
Item 7.01: Regulation FD Disclosure
- FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path
- COMPANION-002 Phase 2/3 data planned for FDA discussion before a potential BLA submission
AI summaries of CMPX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CMPX
Don't miss the next CMPX filing
- Alerts as it files. A push when CMPX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CMPX, by share count.
- Ask anything. An AI agent that reads every CMPX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lerner Neil | Buy | Nov 17, 2026 | 10,000 | $0.59 |
| Lerner Neil | Buy | Oct 1, 2026 | 20,000 | $0.92 |
| Lerner Neil | Buy | Sep 24, 2026 | 2,500 | $1.14 |
| Anderman Jonathan | A | Apr 29, 2026 | 25,000 | $1.89 |
| Anderman Jonathan | Buy | Apr 29, 2026 | 25,000 | $1.89 |
| Lerner Neil | A | Apr 29, 2026 | 15,000 | $1.89 |
| Lerner Neil | Buy | Apr 29, 2026 | 15,000 | $1.89 |
| Schuetz Thomas J. | F | Feb 8, 2026 | 36,687 | $6.52 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $850K | $0 |
| Operating Income | -$50.4M | -$56.6M | -$72.8M |
| Net Income | -$42.5M | -$49.4M | -$66.5M |
| Op. Margin | - | -6661.8% | - |
| Net Margin | - | -5808.8% | - |
| Balance Sheet | |||
| Total Assets | - | $140.4M | $219.6M |
| Equity | - | $125.2M | $196.8M |
| ROE | - | -39.4% | -33.8% |
| Per Share | |||
| EPS | $-0.33 | $-0.36 | $-0.42 |
| Cash Flow | |||
| Operating CF | -$40.6M | -$44.9M | -$49.1M |
| CapEx | - | $44K | $25K |
Source: XBRL data in Compass Therapeutics, Inc. (CMPX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CMPX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $49.4M |
| Q2 2026 | 26 | $118.8M |
| Q1 2026 | 29 | $200.1M |
| Q4 2025 | 25 | $219.5M |
| Q3 2025 | 21 | $146.6M |
| Q2 2025 | 24 | $84.3M |
| Q1 2025 | 22 | $51.6M |
| Q4 2024 | 14 | $32.5M |
- D.E. Shaw & Co+1.54M (+754%)
- Morgan Stanley+759.5K (+103%)
- Two Sigma Investments+449.1K (+140%)
- Dimensional Fund Advisors+314.5K (+58%)
- BlackRock+112.8K (+1%)
- State Street Corp−2.22M (-22%)
- Vanguard Portfolio Management LLC−1.69M (-45%)
- AQR Capital Management−1.53M (-44%)
- Citadel Advisors LLC−1.43M (-40%)
- JPMorgan Chase & Co−485.5K (-62%)
- Ameriprise Financial+107.8K
- FMR LLC (Fidelity)−1.21M
- Blackstone Group−899.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CMPX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 20, 2026 | - | Analysis | - |
| 4 | Nov 18, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 29, 2026 | - | - | - |
| 4 | Apr 29, 2026 | - | - | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Feb 10, 2026 | - | - | |
| SC 13G | Jan 21, 2026 | - | - | |
| 4 | Jan 12, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CMPX SEC filings: frequently asked questions
Are CMPX insiders buying or selling?
In the last 90 days, Compass Therapeutics, Inc. (CMPX) officers, directors and 10% owners reported 3 open-market purchases worth $27,150 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CMPX stock?
As of September 30, 2026, the largest Compass Therapeutics, Inc. (CMPX) holders among the 13F filers tracked by SignalX were BlackRock ($11.9 million), State Street Corp ($8.0 million), Vanguard Capital Management LLC ($6.2 million), Millennium Management ($4.9 million), Goldman Sachs Group ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CMPX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Compass Therapeutics, Inc. (CMPX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $66.5 million. Diluted EPS was -$0.42. The figures come from the XBRL data in the 10-K.
What did CMPX report in its latest 8-K?
Compass Therapeutics, Inc. (CMPX) filed an 8-K on November 20, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days.
What are the latest CMPX SEC filings?
Compass Therapeutics, Inc. (CMPX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 18, 2026.
What is CMPX's SEC CIK number?
Compass Therapeutics, Inc. (CMPX)'s SEC Central Index Key (CIK) is 1738021. EDGAR lists every CMPX filing under that number.
Ask anything about CMPX
The research agent reads CMPX's filings, financials, insider trades and 13F holders, then answers with sources.